Clinical trial
A 24-Month Phase Ib Multi-Center, Open Label, Single Arm Study to Evaluate the Safety of Intravitreal APL-2 Therapy in Patients Diagnosed With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
NCT03777332 is registered in ClinicalTrials.gov with Apellis Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 24-Month Phase Ib Multi-Center, Open Label, Single Arm Study to Evaluate the Safety of Intravitreal APL-2 Therapy in Patients Diagnosed With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 5, 2018
- Completion date
- April 1, 2021
- Enrollment
- 19 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.